Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

AI-Driven Prediction of Hospital-Acquired Infections With EHR

NCT06791382 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2023-02-01
Last updated
2025-04-17

Condition(s) studied

Hospital-acquired Infections

Investigational drug(s) / intervention(s)

AI-Based Diagnostic and Prognostic Model

AI-Based Diagnostic and Prognostic Model: This intervention involves an AI system that integrates multimodal data, including patient medical history, laboratory test results, clinical observations, and treatment data, to predict the risk of hospital-acquired infections (HAIs). The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of patients at risk for infections. By analyzing historical health data, the model aims to predict potential infection developments, improving early detection, prevention strategies, and patient outcomes in hospital settings.

Study summary

This is a multi-center, clinical study designed to evaluate the application and effectiveness of an AI-assisted predictive model for identifying and diagnosing infection, leveraging multimodal health data.

Eligibility

Sex
ALL
Min age
0 Years
Max age
90 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Patients with complete and accessible EHR data, including medical history, laboratory test results, treatment regimens, clinical observations, and infection history. 2. Patients who have been admitted to the participating hospital or healthcare facility during the study period. 3. All participants must provide informed consent to use their health data for research purposes. Exclusion Criteria: 1. Patients with incomplete or missing critical EHR data, such as lab results, medical history, or treatment details, which are necessary for infection prediction. 2. Patients who have severe cognitive disorders, dementia, or conditions that prevent them from providing informed consent or participating in the study. 3. Patients who have not been admitted to the hospital during the study period or who are receiving outpatient care only. 4. Patients with terminal conditions where infection prediction may not be applicable to the clinical goals of the study.

Primary outcome measure(s)

  • Area Under the Curve (AUC) — 1 year
    AUC of the ROC curve, used to quantify diagnostic accuracy. No unit (a ratio or percentage, typically expressed as a number between 0 and 1).
  • F1 Score — 1 year
    The F1 score is the harmonic mean of precision and sensitivity (recall). It is a good measure of the model's ability to identify both true positives and minimize false positives, especially in cases where the classes are imbalanced (e.g., when the number of healthy cases is much higher than disease cases). The F1 score ranges from 0 to 1, with 1 indicating perfect precision and recall.

Trial sites (2)

FacilityCityRegionStatus
First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang Recruiting
Second Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06791382 on ClinicalTrials.gov ↗ ← All trials in China